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Objective: Cerebral cavernous malformation type III (CCM3) is asso-
ciated with null mutations in programmed cell death 10 (PDCD10 or 
CCM3) and is characterized by vessel dilation and increased blood–
brain barrier (BBB) permeability, leading to cerebral hemorrhage. 
Our lab demonstrated that the absence of CCM3 in a mouse brain 
microvascular endothelial cell (mBEC) line leads to increased con-
nexin 43 (Cx43) expression, gap and tight junction (TJ) remodeling, 
and increased permeability. Absence of CCM3 also leads to increased 
expression of a 20 kDa Cx43 isoform (20-Cx43). Our study objectives 
include analyzing the role of 20-Cx43 in increased permeability and TJ 
complex reorganization in CCM3 knockdown (CCM3KD) mBECs and 
dissecting signaling pathways involved in 20-Cx43 expression.
Methods: The role of 20-Cx43 in brain endothelial barrier permeability 
was analyzed in CCM3KD mBECs, transfected with CCM3 siRNA, and 
mBECs overexpressing 20-Cx43. Morphological and functional altera-
tions of CCM3KD and 20-Cx43-overexpressing mBECs were analyzed 
through immunoblotting and immunofluorescent staining, FRET anal-
ysis, and transendothelial electrical resistance (TEER) assays. To assess 
whether the 20-Cx43 is a product of cleavage or internal translation, 
CCM3KD mBECs were treated with Batimastat, an MMP inhibitor, or 
transfected with mitogen-activated protein kinase (MAPK)-interacting 
kinase (MNK) or mammalian target of rapamycin (mTOR) siRNA. Fol-
lowing inhibitor treatment or transfection, 20-Cx43 expression was 
determined through immunoblotting.
Results: 20-Cx43 overexpression causes increased brain endothelial 
permeability and TJ reorganization, as 20-Cx43-overexpressing mBECs 
had decreased Claudin-5 and zonula occludens-1 (ZO-1) expression, 
disrupted ZO-1 incorporation into TJ complexes, and decreased Clau-
din-5/ZO-1 interaction. Treatment with the MMP inhibitor did not 
decrease 20-Cx43 expression in CCM3KD cells, indicating that 20-Cx43 
is not a cleavage product. 20-Cx43 expression, however, was altered 
when signaling pathways regulating internal translation were inhib-
ited. While inhibiting mTOR signaling upregulates 20-Cx43 expression, 
MNK inhibition decreases 20-Cx43 expression, suggesting 20-Cx43 is 
an internal translation product.
Conclusion: Generated through internal translation, 20-Cx43 is 
directly involved in TJ complex reorganization and brain endothelial 
barrier permeability in CCM3KD mBECs.
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Objective: Intranasal route can non-invasively transport IgG antibod-
ies to the central nervous system (CNS) via olfactory and trigeminal 
nerve pathways in the nasal mucosae (1,2), bypassing CNS barriers 
to access perivascular spaces around cerebral blood vessels (3). Here, 
we investigated the variations in intranasal (IN) antibody distribution 
in the CNS with time and effect on pathology which remain largely 
undiscussed. We further examined expression differences of neonatal 
Fc receptor (FcRn) on primary cell cultures and brain sections of rats, 
mice and transgenic murine models.
Methods: Radiolabeled IgG was intranasally applied to similar-aged 
wild-type C57BL6/J (WT) and transgenic APPswe/PS1dE9 (AD) mice 
over 30 min or 6 h. A separate group of AD mice were subjected to 
14 weeks of IN exposure of a targeted antibody (6E10). Animals were 
euthanized at 30 min/6 h/15 weeks post first IN dose by saline perfu-
sion. Whole brains from acute and semi-chronic IgG exposure were 
post-fixed and processed for gamma-counting/autoradiography/
immunohistochemistry (IHC). Hemibrains from chronic IgG exposure 
were either post-fixed for sectioning and Thioflavin-S (ThioS) staining 
or processed for ELISA. Images were quantified using a custom Fiji/
ImageJ program. Cell cultures underwent IHC and fluorescence imag-
ing to validate anti-FcRn antibodies (1G3, M-255, H-4) prior to ex vivo 
IHC.
Results: Rapid IgG exposure was observed in WT and AD cortical 
regions, albeit higher for AD mice. IgG exposure spread to subcortical 
regions over 6 h. Chronic IN exposure of a targeted IgG led to a signifi-
cant reduction in Thioflavin-S staining in the olfactory bulb and frontal 
cortex regions. No significant differences were observed in Aβ levels 
with ELISA. In the parenchyma, FcRn immunoreactivity was mostly 
neuronal and astrocytic in rats, non-neuronal, non-astrocytic in WT 
mice and perivascular in AD mice. In vitro FcRn immunolabeling was 
negative for rat and mouse endothelial cells, negative for mouse astro-
cytes and inconclusive for rat astrocytes.
Conclusion: IgG distribution in the murine CNS increases with time 
and potentially leads to reduction in pathology via target engagement 
and redistribution. IgG exposure can be variable across species and 
transgenic models, potentially due to the alteration of Fc receptors in 
the CNS
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Objective: Mycobacterium tuberculosis (Mtb) can disseminate from 
the lung to the central nervous system (CNS) leading to tuberculous 
meningitis, which causes serious neurological damage with a high 
mortality rate. The mechanism of bacterial dissemination into the CNS 
is not known. Previously we showed that infected dendritic cells (DCs) 
mediate systemic dissemination and subsequent granuloma forma-
tion of Mycobacterium bovis bacillus Calmette-Guérin (BCG) and Mtb. 
The objective of this study was to test the role of mycobacterium-
infected DC driven cell aggregation and bacterial dissemination across 
the BBB in vitro.
Methods: Primary bone marrow-derived DCs from CD11c-eYFP mice 
were used to study the migration capacity of mycobacterium-infected 
DCs in real time with fluorescent confocal microscopy. To investigate 
the dissemination of BCG and Mtb into the brain we developed a 
unique in vitro granuloma model combined with an in vitro double 
BBB co-culture model consisting of primary mouse brain endothelial 
cells and astroglia. In this model, BCG or Mtb-infected DCs were co-
cultured with peripheral blood mononuclear cells (PBMCs) isolated 
from P25 Mycobacterium antigen-specific T-cell receptor transgenic 
mice. To reveal the mechanism of cell migration and cellular aggregate 
formation on brain endothelial cells iNOS, MMP9 and TNFα-KO mice 
were used.
Results: First we show that BCG infection decreases the migration 
capacity of DCs. Co-culture of mycobacterium-infected DCs and P25 
transgenic mouse-derived PBMCs leads to cellular aggregate for-
mation on brain endothelial cells which facilitate transmigration of 
infected cells across the BBB. Barrier properties of the BBB are impaired 
in the vicinity of cell clusters and endothelial ICAM-1 and VCAM-1 
adhesion molecule expression is elevated. We revealed a double role 
of iNOS in the system: it causes BBB damage through reactive oxy-
gen stress but by itself it slows down DC cell migration through the 
endothelial monolayer.
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Conclusion: This novel and unique in vitro BBB-granuloma combined 
model suggests that mycobacterium-infected DC induced cell aggre-
gation on the surface of brain vessels promotes Mtb dissemination 
into the CNS.
Grant Support: NIH grants 3R01NS076946; R01HL128778-01; 
HC128778-01 and T32GM081061.
Reference
1. Harding JS, Rayasam A, Schreiber HA, Fabry Z, Sandor M. Mycobacterium‑
infected dendritic cells disseminate granulomatous inflammation. Sci 
Rep. 2015; 5:15248.
A37 
Dendrimers‑new hope for the treatment of Alzheimer’s disease
Jerzy Leszek
Wroclaw Medical University, Wroclaw, PO, Poland
Correspondence: Jerzy Leszek ‑ jerzy.leszek@umed.wroc.pl 
Fluids and Barriers of the CNS 2019, 16(Suppl 1):A37
Objective: The lack of effective treatment for Alzheimer’s disease 
(AD) stems mainly from the incomplete understanding of AD causes. 
Currently there are several hypothesis which try to explain the early 
molecular mechanisms of AD pathogenesis.
Methods: Considering that AD is a multi-factorial disease with several 
pathogenic mechanisms and pathways, a multifunctional nanotech-
nology approach may be needed to target its main molecular culprits. 
To very early diagnosis of AD we need to have an affordable, ultrasen-
sitive and selective molecular detection methods. Ultra-low concentra-
tions of protein biomarkers (e.g. ADDL-amyloid-Beta-derived diffusible 
ligands) which have been implicated in the pathogenesis of AD, is 
possible to detect, owing to carrier dendrimers -polymeric molecules 
chemically synthesized with well-defined shape size and nanoscopic 
physicochemical properties reminiscent of proteins
Results: Our studies have revealed that dendrimers have ability to 
prevent aggregation and fibrillation of proteins involved in AD. Some 
of dendrimers were demonstrated to cross blood–brain barrier, which 
legitimized research research on these compounds as potential drugs 
for neurological disorders like AD. Recent our studies have revealed 
that dendrimers possess the intrinsic ability to localize in cells associ-
ated with neuroinflammation (activated microglia and astrocytes) and 
thus can be used in neuroinflammation therapy
Conclusion: Above/mentioned findings may be significance in the 
context of potential application of dendrimers as drug carriers or 
active compounds per se. According to opinion the authors of this 
presentation, they are promising macromolecules for further inves-
tigations on their applicable in neurodegenerative disorders, for 
instance AD
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Objective: To optimize post-differentiation freeze, thaw, and culture 
conditions for induced pluripotent stem cell-derived brain micro-
vascular endothelial cell (iPSC-BMEC) maturation, functionality, and 
reproducibility.
Methods: Human iPSCs were spontaneously differentiated into 
BMECs (protocol based on Lippmann et al. Nat Biotech 2012). Disso-
ciation and sub-culture conditions were investigated using Design of 
Experiments (DoE), an unbiased method based on structured statisti-
cal analysis of variance (ANOVA). DoE efficiently identifies interactions 
amongst experimental variables and predicts responses. Our design 
focused on maximizing trans-endothelial electrical resistance (TEER). 
We incorporated a Mantis liquid handler to execute precise culture 
conditions in 96-well transwell systems and measured TEER over time. 
Top hit conditions were validated on multiple batches of iPSC-BMECs, 
these included post-thaw cell viability, hourly TEER reads, and immu-
nocytochemistry (ICC).
Results: We have identified a robust cryopreservation method, time 
course and medium formulation for sub-culturing spontaneously 
differentiated iPSC-BMEC. The optimized cryopreservation protocol 
yields high cell viability recovery allowing the ability to produce 
bulk batches of iPSC-BMECs, thereby minimizing interexperimental 
variability. Surprisingly, we found that the removal of retinoic acid 
and the extension to at least 7 days in culture reproducibly resulted 
in prolonged high TEER, approximately 500 ohms * cm2 greater than 
TEER peak at 48 h, in iPSC-BMEC mono-culture transwells. Our sub-
culture method generates iPSC-BMECs that express the endothelial 
surface marker PECAM1, relevant blood–brain barrier (BBB) tight 
junction proteins (claudin-5, ZO-1, occludin), and transporters 
enriched on brain microvessels (Glut-1, transferrin receptor, insulin 
receptor).
Conclusion: We demonstrate the power of applying DoE to fine-
tune complex culture conditions to maximize cell performance. Our 
cryopreservation and sub-culture protocols robustly produce func-
tional endothelial cells of the BBB that are suited to address basic 
cerebral vascular biology questions, study the vascular phenotype 
of neurological disorders, and enable high-throughput screening for 
drug discovery.
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The blood brain barrier (BBB) protects the brain from toxic agents in 
the blood(Abbott and Friedman 2012). From a drug safety perspec-
tive, disruption to the BBB integrity or functionality by a therapeutic 
agent has been shown to be associated with the risks of neuroin-
flammation and neurodegeneration. For example, the administra-
tion of the CAR-T therapy has been shown to potentially increase 
BBB permeability, a risk factor for neurotoxicity (Gust, Hay et al. 
2017). Therefore, it is important to have a functional in vitro human 
BBB model to understand and assess the effects of a drug candidate 
which potentially trigger immune cell infiltration and direct interac-
tions of the endothelial cells in the BBB.
We have developed a human in vitro BBB model from the differentia-
tion of human pluripotent stem cells (hiPSCs). When compared with 
the primary human brain endothelial cells, the human iPSC derived 
BBB model showed robust structural and functional characteristics. 
The in vitro BBB model exhibited barrier integrity through sustained 
trans endothelial electrical resistance (TEER) greater than 1500 Ohms.
cm2, closely reflecting the in vivo BBB.
We are further investigating the effects of normoxia and hypoxia 
conditions, on the functionality and integrity of the BBB. Effects of 
inflammatory cytokines on BBB equilibrium is also being tested. The 
development of the human in vitro BBB model will provide a valuable 
tool to study drug related disruption of BBB and help in selecting com-
pounds that are safe to BBB function.
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